Aspen Investment Management Inc Grows Stock Position in Amgen Inc. $AMGN

Aspen Investment Management Inc grew its position in Amgen Inc. (NASDAQ:AMGN) by 30.5% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 7,451 shares of the medical research company’s stock after acquiring an additional 1,742 shares during the quarter. Aspen Investment Management Inc’s holdings in Amgen were worth $2,439,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in AMGN. Robeco Institutional Asset Management B.V. lifted its position in Amgen by 10.0% during the fourth quarter. Robeco Institutional Asset Management B.V. now owns 481,453 shares of the medical research company’s stock worth $157,584,000 after buying an additional 43,884 shares in the last quarter. Curtis Advisory Group LLC purchased a new position in Amgen during the fourth quarter worth approximately $1,669,000. Jones Financial Companies Lllp lifted its position in Amgen by 18.2% during the third quarter. Jones Financial Companies Lllp now owns 39,778 shares of the medical research company’s stock worth $10,888,000 after buying an additional 6,115 shares in the last quarter. Adell Harriman & Carpenter Inc. lifted its position in Amgen by 7.9% during the fourth quarter. Adell Harriman & Carpenter Inc. now owns 22,008 shares of the medical research company’s stock worth $7,204,000 after buying an additional 1,609 shares in the last quarter. Finally, Lockheed Martin Investment Management Co. purchased a new position in Amgen during the third quarter worth approximately $2,624,000. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Insider Buying and Selling at Amgen

In other news, SVP Nancy A. Grygiel sold 1,237 shares of Amgen stock in a transaction on Monday, May 4th. The stock was sold at an average price of $323.73, for a total value of $400,454.01. Following the completion of the sale, the senior vice president directly owned 7,009 shares of the company’s stock, valued at approximately $2,269,023.57. The trade was a 15.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Insiders own 0.85% of the company’s stock.

Amgen Price Performance

NASDAQ:AMGN opened at $331.57 on Thursday. Amgen Inc. has a 52 week low of $267.83 and a 52 week high of $391.29. The company has a quick ratio of 1.01, a current ratio of 1.26 and a debt-to-equity ratio of 5.65. The company has a market capitalization of $178.94 billion, a P/E ratio of 23.07, a P/E/G ratio of 3.32 and a beta of 0.44. The stock’s fifty day moving average is $346.62 and its two-hundred day moving average is $344.14.

Amgen (NASDAQ:AMGN) last posted its earnings results on Thursday, April 30th. The medical research company reported $5.15 EPS for the quarter, beating analysts’ consensus estimates of $4.77 by $0.38. Amgen had a return on equity of 137.41% and a net margin of 20.96%.The company had revenue of $8.62 billion for the quarter, compared to the consensus estimate of $8.58 billion. During the same quarter in the previous year, the business earned $4.90 earnings per share. The company’s revenue for the quarter was up 5.8% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. Equities analysts expect that Amgen Inc. will post 22.37 EPS for the current year.

Amgen Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 5th. Shareholders of record on Friday, May 15th will be given a $2.52 dividend. The ex-dividend date is Friday, May 15th. This represents a $10.08 dividend on an annualized basis and a yield of 3.0%. Amgen’s payout ratio is currently 70.15%.

Analyst Ratings Changes

A number of brokerages recently commented on AMGN. Wells Fargo & Company lifted their price objective on Amgen from $375.00 to $390.00 and gave the stock an “equal weight” rating in a research report on Thursday, March 19th. The Goldman Sachs Group lifted their price objective on Amgen from $415.00 to $425.00 and gave the stock a “buy” rating in a research report on Friday, May 1st. UBS Group lifted their price objective on Amgen from $390.00 to $400.00 and gave the stock a “buy” rating in a research report on Monday, April 13th. Mizuho lifted their price objective on Amgen from $280.00 to $295.00 and gave the stock an “outperform” rating in a research report on Tuesday, February 10th. Finally, Wall Street Zen downgraded Amgen from a “buy” rating to a “hold” rating in a research report on Saturday, April 25th. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, fourteen have assigned a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $355.19.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.